Study summary

Aspirin did not prevent relapse after treatment of liver metastases

ASAC trial (aspirin after liver metastases) · 428 people, phase 3 · Published September 2026, Lancet Gastroenterology & Hepatology

What was tested

Aspirin 160 mg daily or placebo for up to 3 years after curative treatment of colorectal cancer liver metastases, not selected by tumor mutations.

What they found

What it means

Aspirin should not be routinely used after liver metastasis treatment without a specific tumor marker.

Lancet Gastroenterol Hepatol, via PubMed ↗ Trial record NCT03326791 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.